Combined Detection of Urine Specific Gravity and BK Viruria on Prediction of BK Polyomavirus Nephropathy in Kidney Transplant Recipients
Introduction
BK polyomavirus-associated nephropathy (BKPyVAN) is a significant cause of renal allograft dysfunction and failure in kidney transplant recipients. Current diagnostic methods, including urine cytology and quantitative polymerase chain reaction (qPCR) for BKPyV-DNA in urine and plasma, lack specificity for intra-renal disease. Definitive diagnosis requires invasive kidney biopsy, which carries risks and sampling limitations. Morning urine specific gravity (MUSG), a routine indicator of renal concentrating ability, may reflect tubular injury caused by BKPyV infection. This study evaluated the diagnostic utility of MUSG in distinguishing BKPyVAN from isolated BK viruria and T cell-mediated rejection (TCMR).
Methods
A retrospective analysis included 87 kidney transplant recipients categorized into four groups: BKPyVAN (n=27), isolated BK viruria (n=22), TCMR (n=18), and stable graft function (control, n=20). MUSG, serum creatinine (Scr), and BKPyV-DNA loads in urine and plasma were measured at biopsy and during 24 months of follow-up. MUSG was assessed using a Bayer Clinitek 50 analyzer. BKPyV loads were quantified via qPCR targeting the VP1 gene. BKPyVAN was confirmed via renal biopsy with SV40 immunohistochemistry. Statistical analyses compared MUSG across groups and evaluated diagnostic performance using receiver operating characteristic (ROC) curves.
Results
Study Cohort
Baseline characteristics revealed no significant differences in age, sex, or immunosuppressive regimens between groups. Baseline Scr was higher in BKPyVAN (158.1 ± 45.0 mmol/L) and TCMR (187.8 ± 58.0 mmol/L) groups compared to isolated BK viruria (100.3 ± 26.0 mmol/L) and control groups (94.0 ± 3.0 mmol/L). Urine and plasma BKPyV loads were significantly higher in BKPyVAN than isolated BK viruria (urine: 2.9×10⁹ vs. 2.2×10⁵ copies/mL; plasma: 1.3×10³ vs. 0 copies/mL).
MUSG Comparisons
At biopsy, MUSG was significantly lower in BKPyVAN (1.008 ± 0.003) than in isolated BK viruria (1.013 ± 0.004, P < 0.001), TCMR (1.011 ± 0.003, P = 0.027), and control groups (1.014 ± 0.006, P < 0.001). No significant MUSG differences existed between isolated BK viruria, TCMR, and control groups. Post-treatment, MUSG in BKPyVAN patients increased progressively, aligning with declines in viral loads. By 3 months, MUSG rose to 1.012 ± 0.003 (P < 0.001 vs. baseline), correlating with reduced urine (7.9×10⁶ vs. 2.9×10⁹ copies/mL) and plasma (1.3×10⁴ vs. 1.3×10³ copies/mL) BKPyV loads.
Diagnostic Performance of MUSG
ROC analysis for discriminating BKPyVAN from non-BKPyVAN (isolated BK viruria, TCMR, control) yielded an AUC of 0.803 (95% CI: 0.721–0.937), with an optimal MUSG cutoff of 1.009 (sensitivity: 70%, specificity: 80%). Differentiating BKPyVAN from TCMR, the AUC was 0.811 (95% CI: 0.687–0.934), with a cutoff of 1.010 (sensitivity: 74%, specificity: 61%). For distinguishing BKPyVAN from isolated BK viruria, the AUC was 0.852 (95% CI: 0.726–0.940), cutoff 1.009 (sensitivity: 70%, specificity: 86%).
Pathological Correlation
No significant correlation was found between MUSG and histological scores (tubulitis, interstitial inflammation, fibrosis) in BKPyVAN. Repeated biopsies in 19 BKPyVAN patients showed reduced cytopathic changes (0.579 ± 0.507 vs. 1.684 ± 0.820, P < 0.001) and improved MUSG (1.013 ± 0.003 vs. 1.009 ± 0.003, P < 0.001) post-treatment.
Discussion
This study highlights MUSG as a non-invasive biomarker for BKPyVAN. The significant MUSG reduction in BKPyVAN reflects tubular injury from viral replication in medullary collecting ducts, impairing urine concentration. Unlike isolated BK viruria (transitional epithelial infection) or TCMR (cortical tubulitis), BKPyVAN uniquely affects medullary regions, explaining the distinct MUSG pattern. The ROC-derived MUSG cutoff of 1.009 offers practical diagnostic value, particularly in resource-limited settings where biopsies are challenging.
MUSG dynamics also mirrored therapeutic responses, rising with viral load reduction after immunosuppression adjustment. This aligns with the hypothesis that tubular function recovery accompanies viral clearance. Notably, MUSG’s diagnostic performance (AUC 0.803–0.852) surpasses traditional markers like plasma qPCR (specificity ~60%), supporting its role in early BKPyVAN detection.
Clinical Implications
Differentiating BKPyVAN from TCMR is critical, as treatment strategies oppose: immunosuppression reduction for BKPyVAN versus intensification for TCMR. MUSG’s ability to distinguish these entities (AUC 0.811) addresses a key clinical dilemma. Additionally, MUSG monitoring post-diagnosis provides real-time feedback on tubular recovery, complementing viral load measurements.
Limitations
The retrospective design and single-center cohort limit generalizability. Sample size constraints precluded subgroup analyses by BKPyVAN stage. Future studies should validate MUSG in larger, multicenter cohorts and explore its integration with other biomarkers (e.g., urinary cytokines) for enhanced diagnostic accuracy.
Conclusion
Combined MUSG and BK viruria assessment provides a reliable, non-invasive method for diagnosing BKPyVAN and distinguishing it from TCMR in kidney transplant recipients. MUSG ≤1.009 strongly indicates BKPyVAN, while serial measurements track therapeutic efficacy. This approach reduces reliance on invasive biopsies, enabling timely clinical decisions to preserve allograft function.
doi.org/10.1097/CM9.0000000000000579
Was this helpful?
0 / 0